The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...
HAYWARD, Calif., February 26, 2025--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a well-funded drug startup run by Merck & Co.’s former research chief, has raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback